08:00 , Dec 3, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Co-crystal structure of human cytomegalovirus (CMV) glycoprotein B and a broadly neutralizing antibody (bNAb) against CMV to aid vaccine design

Drug platforms TECHNOLOGY: Structural analyses Vical Inc. Astellas Pharma Inc. ASP0113 Sanofi CMV gB/MF59 GlaxoSmithKline plc GSK1492903 human cytomegalovirus (CMV) glycoprotein B...
07:00 , Apr 1, 2013 |  BioCentury  |  Emerging Company Profile

Hookipa: Next wave vector

Hookipa Biotech AG is using its Vaxwave technology to discover and develop viral vectors designed to elicit B cell and CD8+ T cell immune responses without concurrent induction of antibodies that block vector re-administration. A...
07:00 , Mar 23, 2009 |  BC Week In Review  |  Clinical News

CMV gB/MF59: Phase II data

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID) published data in the New England Journal of Medicine showing that treatment with CMV gB/MF59 resulted in a significantly lower infection rate at 42...